Novo Holdings completes third investment in Asia in one month

Novo Holdings, which manages the Novo Nordisk Foundation's assets, has invested in an Asian company for the third time in one month. The latest investment was in Esco Lifesciences group.

Photo: Novo Holdings / PR

The owner of Novo Nordisk, Novo Holdings, is lavishing investments on the world's largest continent, most recently through the establishment of an Asian office in Singapore.

On Thursday, the Danish fund reports that alongside Vivo Capital, it has co-led a series a financing round worth USD 200m in Esco Lifesciences Group which produces life science tools and services.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs